Related news:Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD - Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy
Regeneron
Bookmark
ShareRegeneron is a company. It is located in Tarrytown, the United States and was founded in 1988. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Tarrytown
- state: NY
- country: United States
- sector: Health Care
- industry: Biotechnology
- foundation year: 1988
- CEO: Dr. Leonard S. Schleifer M.D., Ph.D.
Classified as: organization
Business
Regeneron is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,550,070 companies in our database.
- Assets: 25.4B $
- Debt: 2.7B $
- Employees: 10,492 people
- Free cash flow: 5.8B $
- Market cap: 76.2B $
- Profits: 8.1B $
- Revenues: 16.5B $
Stocks from Regeneron:
Talking Points:
- Regeneron Pharmaceuticals: Delivering Lifetransforming Medicines
- Regeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need. Learn more.
- Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here: https:
- t.co
- EuFDUdQQ5E
- Create the future you believe in. | Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we're creating whole new ways of thinking about science, manufacturing and commercialization.
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Learn more about talking points
